- Home
- SYM vs INTS Comparison
SYM vs INTS Comparison
Compare SYM & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SYM
- INTS
- Stock Information
- Founded
- SYM 2005
- INTS 2012
- Country
- SYM United States
- INTS United States
- Employees
- SYM N/A
- INTS 16
- Industry
- SYM Industrial Machinery/Components
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- SYM Industrials
- INTS Health Care
- Exchange
- SYM Nasdaq
- INTS Nasdaq
- Market Cap
- SYM N/A
- INTS 30.8M
- IPO Year
- SYM N/A
- INTS 2023
- Fundamental
- Price
- SYM $20.90
- INTS $2.06
- Analyst Decision
- SYM Buy
- INTS Strong Buy
- Analyst Count
- SYM 17
- INTS 3
- Target Price
- SYM $39.60
- INTS $8.50
- AVG Volume (30 Days)
- SYM 1.2M
- INTS 38.4K
- Earning Date
- SYM 05-05-2025
- INTS 03-13-2025
- Dividend Yield
- SYM N/A
- INTS N/A
- EPS Growth
- SYM N/A
- INTS N/A
- EPS
- SYM N/A
- INTS N/A
- Revenue
- SYM $1,914,929,000.00
- INTS N/A
- Revenue This Year
- SYM $27.67
- INTS N/A
- Revenue Next Year
- SYM $32.46
- INTS N/A
- P/E Ratio
- SYM N/A
- INTS N/A
- Revenue Growth
- SYM 43.92
- INTS N/A
- 52 Week Low
- SYM $17.11
- INTS $1.50
- 52 Week High
- SYM $48.98
- INTS $5.28
- Technical
- Relative Strength Index (RSI)
- SYM 42.06
- INTS 46.37
- Support Level
- SYM $19.25
- INTS $1.88
- Resistance Level
- SYM $23.85
- INTS $2.18
- Average True Range (ATR)
- SYM 1.23
- INTS 0.21
- MACD
- SYM 0.06
- INTS -0.01
- Stochastic Oscillator
- SYM 35.87
- INTS 39.73
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.